Publications by authors named "C Tekin"

Acute generalized exanthematous pustulosis (AGEP) is a rare drug eruption characterized by the rapid occurrence of many sterile, non-follicular pustules, neutrophilic leukocytosis, high fever and spontaneous resolution usually within two weeks. The distribution of rash predilection in the trunk and intertriginous regions. In treatment, the causative drug must be initially discontinued.

View Article and Find Full Text PDF

Total resection of glioblastoma (GB) tumors is nearly impossible, and systemic administration of temozolomide (TMZ) is often inadequate. This study presents a hybrid layered composite nanofiber mesh (LHN) designed for localized treatment in GB tumor bed. The LHN, consisting of polyvinyl alcohol and core-shell polylactic acid layers, was loaded with TMZ and rutin.

View Article and Find Full Text PDF

Introduction: First-line treatment of persistent, recurrent, or metastatic (advanced) cervical cancer in patients who have a combined positive score (CPS) ≥ 1 with pembrolizumab + chemotherapy versus standard-of-care chemotherapy provides meaningful improvements in overall survival. We conducted a cost-effectiveness analysis from a US payer perspective. A societal perspective scenario was also considered, including productivity gains.

View Article and Find Full Text PDF

Supramolecular crystals arise from noncovalent interactions between macromonomers and allow for the engineering of dynamic functional materials. For two-dimensional (2D) crystals, the substrate surface can induce the formation of new polymorphs not available in solution, adding a layer of complexity to the supramolecular self-assembly process. Despite extensive studies on the 2D self-assembly of supramolecular crystals, unknowns remain regarding substrate-monomer interactions and the effects on network self-assembly and defect repair.

View Article and Find Full Text PDF
Article Synopsis
  • - In the KEYNOTE-826 study, pembrolizumab combined with chemotherapy significantly boosted overall survival (OS) and progression-free survival (PFS) in patients with advanced cervical cancer, with specific attention to those using bevacizumab.
  • - The analysis included 617 patients, with a majority excluded from bevacizumab due to medical reasons; outcomes showed that those receiving pembrolizumab generally had better survival metrics, regardless of bevacizumab use.
  • - Patients on pembrolizumab experienced a high rate of severe side effects, with 74% suffering grade ≥3 treatment-related adverse events in the bevacizumab group.
View Article and Find Full Text PDF